Table 2.

Treatment and Outcomes of 107 Seasonal Influenza Episodes in Children with Cancer.

	Overall n = 107	Leukemia/Lymphoma n = 69 (64)	Solid Tumor n = 19 (18)	HCST n = 19 (18)	Pa
Received antiviral therapy (%)	80 (75)	54 (78)	9 (47)	17 (89)	0.01
Type of antiviral agent (n = 80)b
Oseltamivir	73 (91)	52 (96)	7 (78)	14 (82)
Rimantadine	2 (3)	1 (2)	1 (11)	0
Amantadine	2 (3)	1 (2)	0	1 (6)
Oseltamivir + rimantidine	2 (3)	0	1 (11)	1 (6)
Oseltamivir + amantadine	1 (1)	0	0	0
Days of antiviral therapy, median (IQR)(n = 80)	5 (5–5)	5 (5–5)	5 (4–5)	5 (5–6)	0.2
No. receiving concurrent antibacterial therapy (%)	92 (86)	66 (96)	14 (74)	12 (63)	<0.001
No. of antimicrobials, median (IQR) (n = 92)	2 (1–3)	2 (1–3)	2 (1–2)	3 (2–5)	0.08
Days of symptoms, median (IQR)(n = 80)	15 (10–21)	15 (10–19)	13 (11–23)	17 (11–37)	0.3
No. hospitalized (%)	66 (64)	46 (67)	10 (53)	10 (53)	0.4
Days of hospitalization, median (IQR) (n = 70)	5 (3–8)	4 (3–7)	5 (4–7)	14 (5–29)	0.01
No. deaths (%)	3 (3)	0 (0)	0 (0)	3 (16)	0.01
No. complications (%) (n = 106)	32 (30)	21 (30)	2 (11)	9 (47)	0.04
No. pneumonia (%) (n = 62)	19 (31)	12 (29)	0 (0)	7 (47)	0.1
No. serious acute complications (%) (n = 106)	8 (7)	4 (6)	0 (0)	4 (21)	0.05
No. with delay in chemotherapy (%) (n = 102)	63 (62)	59 (86)	3 (17)	1 (7)	<0.001
Days therapy delayed, median (IQR) (n = 63)	5 (5–5)	5 (5–5)	5(4–5)	5 (5–6)	0.4

HSCT, hematopoietic stem cell transplant; IQR, interquartile range

^aValues were compared across cancer diagnoses by the Chi square, Fisher’s exact and Kruskall-Wallace test or ANOVA.

^bn indicates number of episodes for which variable was recorded.